Cytori Therapeutics

Cytori Therapeutics (NASDAQ: CYTX) today reports its first quarter 2013 financial results and provides updates on clinical development and commercialization activities. ... read more

Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 9, 2013 at 5:00 PM Eastern Time. ... read more

Cytori Therapeutics (NASDAQ: CYTX) received US Patent No. 8,404,229 (the ‘229 patent) for methods of treating renal diseases using adipose-derived regenerative cells ... read more

Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March 7, 2013 at 5:00 ... read more

Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations ... read more

Cytori Therapeutics (NASDAQ: CYTX) has received a CE Mark in Europe for Intravase®, a reagent intended to be used with Cytori’s Celution® System for preparing safe and optimized ... read more

SAN DIEGO, CA -- (Marketwire) -- 11/11/10 -- Cytori Therapeutics (NASDAQ: CYTX) will be hosting an investor teach-in on cardiac cell therapy on Tuesday, November 16 from 7:00-8:00 AM CT (8:00-9:00 AM ET) from the American Heart Association meeting in Chicago. The goal is to help investors evaluate ... read more